VERTEX PHARMACEUTICALS INC / MA Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price, Beginning Balance (Deprecated 2011-01-31)
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price, Beginning Balance (Deprecated 2011-01-31) of $30.5 for the 12-month period ending 2010-12-31, per its 10-K filed 2011-02-17.
Discontinued › Notes › Compensation Related Costs
us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance · last filed 2011-02-17
- VERTEX PHARMACEUTICALS INC / MA share-based compensation, shares authorized under stock option plans, exercise price range, outstanding options, weighted average exercise price, beginning balance (deprecated 2011-01-31) for fiscal 2010 was $30.50, a 2.80% decline from fiscal 2009.
- VERTEX PHARMACEUTICALS INC / MA share-based compensation, shares authorized under stock option plans, exercise price range, outstanding options, weighted average exercise price, beginning balance (deprecated 2011-01-31) for fiscal 2009 was $31.38.
| Period end | Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price, Beginning Balance (Deprecated 2011-01-31) 12 month |
|---|---|
| 2010-12-31 | $30.50 10-K · filed 2011-02-17 |
| 2009-12-31 | $31.38 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |